Turning your clocks ahead an hour on March 8 for the start of Daylight Savings Time may be known as the unofficial start to spring, but for many, it’s known as the day we lose an hour of sleep. As you prepare to change your clocks on Sunday, take that opportunity to evaluate your sleeping habits. The loss of that hour of sleep can turn minor sleep issues into major ones.
“When we move our clock forward or backward, our internal clock becomes out of sync with the external time,” says Dr. Daniel Shade, Board Certified Sleep Specialist and Director of the AHN Sleep Disorders Center. “The best way to combat this is to expose ourselves to light and let our bodies resynchronize.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447951-remworks-daylight-savings-sleep-coach/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
With the February launch of GOPO® Rosehip with Galactolipids, a natural, plant-based joint care supplement clinically proven to support joint health, the natural supplement is gaining traction and helping millions who suffer joint pain due to age, sports injuries, etc. Used extensively in Europe, GOPO is now available in the U.S. and proven effective in supporting long-term joint mobility and cartilage care.
GOPO Rosehip with Galactolipids is made from 100% specially-cultivated, natural rosehip using a patented extraction process and is the only product of its kind to contain a high level of galactolipids - a key component of the rosehip which may play a valuable role in the care of joints and joint tissues.
To view the multimedia release go to:
http://www.multivu.com/players/English/7918251-new-gopo-joint-care-all-natural-supplement/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced the winners of its 2016 Health Hero Awards (http://www.webmd.com/healthheroes/what-is-hero), recognizing individuals who are changing the healthcare landscape by meeting a health challenge and giving back to others. This year’s winners are Seth Rogen and Lauren Miller Rogen, Ed Damiano, PhD, Betty Ferrell, RN, PhD and Trisha Prabhu.
On November 3, 2016, an accomplished and inspiring lineup of presenters and performers will gather to honor the winners at the 3rd Annual WebMD Health Hero Awards gala, hosted by Good Morning America co-anchor Robin Roberts. This year’s presenters include David Krumholtz, Adam Savage, and Sarah Wynter, with musical performances by A Great Big World and Naturally 7.
To watch the red carpet arrivals as they happen live from the TimesCenter in New York City, follow WebMD on www.facebook.com/webmd beginning at 6:30 PM ET on November 3, and be sure to follow @WebMD on Instagram, Snapchat and Twitter for updates throughout the night with #HealthHeroes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579756-webmd-2016-health-hero-awards/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
To view the multimedia release go to:
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
DePuy Synthes Companies today announced the launch of Hit Play, an educational initiative that encourages those dealing with hip or knee pain to stop settling for a life on ‘pause’ and instead take action to get back to the activities and people they love most.
Osteoarthritis is one of the most common reasons for severe hip or knee pain, affecting nearly 27 million Americans today and will potentially affect up to 67 million people by 2030.1,2 In turn, demand for hip and knee replacements are expected to dramatically increase, yet many women see joint replacement as a “last resort” and often wait until the pain has become unbearable before turning to surgery. Through a series of compelling and relatable content, DePuy Synthes seeks to inspire the millions of people stuck on ‘pause’ due to hip or knee pain to explore joint replacement with a doctor, as a potential viable solution when they Hit Play.
To view the multimedia release go to:
http://www.multivu.com/players/English/79644241-lysol-madison-square-bgca-expose-germs/
